Claims
- 1. A method of treatment of humans suffering from one or more conditions included within the CHDRF Syndrome, comprising the steps of: 1) administering, by a pharmaceutically effective mode, a priming dose of a drug composition comprising a drug substance selected from the group consisting of opiate antagonists, and drugs which substantially equally reduce the amounts of catecholamines bound to catecholamine binding sites for a period of about one to four weeks, and 2) administering a maintenance dose of said selected drug at a dosage level of between 1/10 to 1/2.5 times the priming dose.
- 2. A method according to claim 1 wherein the maintenance dose is administered as a single dose within 3 hours before the patients normal bedtime.
- 3. A method according to claim 1 wherein the drug composition comprises a drug composition which substantially equally reduce the amounts of catecholamines bound to catecholamine binding sites.
- 4. A method according to claim 3 wherein the drug composition further contains a dopamine agonist.
- 5. A method of treating humans suffering from the CHDRF Syndrome, according to claim 3 wherein the drug composition comprises .alpha.-methyltyrosine.
- 6. A method of treating humans suffering from the CHDRF Syndrome according to claim 1 wherein the drug composition further comprises an opiate antagonist.
- 7. A method according to claim 6 wherein the drug composition comprises a single drug.
- 8. A method according to claim 6 wherein the drug composition comprises nalmefene.
- 9. A method according to claim 6 wherein the drug composition comprises 17-cyclopropylmethyl-3-hydroxy-14-methoxy-8.beta.-methylmorphinan-6-one hydrochloride (CHMMO).
- 10. A method according to claim 6 wherein the drug composition comprises a combination of drugs each of which has purely opioid antagonist activity.
- 11. A method according to claim 6 wherein the drug composition comprises a composition containing one or more drugs which have opioid agonist activity.
- 12. A method of treating humans suffering from the CHDRF Syndrome according to claim 6 in which the drug composition with opiate antagonist properties has IC.sub.50 levels for the .mu., .delta., and .kappa. opiate receptors equal within a factor of 10.
- 13. A method of treating humans suffering from the CHDRF Syndrome according to claim 6 in which the drug composition with opiate antagonist properties has IC.sub.50 levels for the .mu., .delta., and .kappa. opiate receptors equal within a factor of three.
- 14. A method of treating humans suffering from the CHDRF Syndrome according to claim 6 in which the drug composition with opiate antagonist properties has IC.sub.50 levels for the .mu., .delta., and .kappa. opiate receptors have ratios such that:
- {(IC.sub.50 .kappa./IC.sub.50 .mu.)<10}, and {(IC.sub.50 .kappa./ IC.sub.50 .delta.)<10}.
- 15. A method of treating humans suffering from the CHDRF Syndrome according to claim 6 in which the drug composition with opiate antagonist properties has IC.sub.50 levels for the .mu., .delta., and .kappa. opiate receptors such that: {(IC.sub.50 .kappa./ IC.sub.50 .mu.)<3}, and {(IC.sub.50 .kappa./ IC.sub.50 .delta.)<3}.
- 16. A method according to claim 6 wherein the drug composition comprises a .kappa.-selective opioid antagonist.
- 17. A method according to claim 6 wherein the drug composition comprises nor-binaltorphimine.
- 18. A method according to claim 1 wherein the condition included within the CHDRF Syndrome, is hyperlipidemia.
- 19. A method according to claim 1 wherein the condition included within the CHDRF Syndrome, is type 2 diabetes.
- 20. A method according to claim 1 wherein the condition included within the CHDRF Syndrome, is impaired glucose tolerance (IGT).
- 21. A method according to claim 1 wherein the condition included within the CHDRF Syndrome, is obesity.
- 22. A method according to claim 1 wherein the condition included within the CHDRF Syndrome, is essential hypertension.
Parent Case Info
This is a continuation-in-part of U.S. Pat. No. 5,878,750 which is a continuation-in-part of U.S. Pat. No. 5,727,570.
Non-Patent Literature Citations (2)
Entry |
Sohel et al. "Influence of Adrenergic Blockers and Antilipemic Agents on Pharmacodynamic Actions of Morphine in Carbon Tetrachloride-Treated Rats." Toxicol Appl Pharmacol 27(3):477-483, Mar. 1974. |
Stern et al. "Lack of Awareness and Treatment of yperlipidemia in Type II Diabetes in a Community Survey." JAMA 262(3):360-4, Jul. 1989. |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
937996 |
Sep 1997 |
|
Parent |
749333 |
Nov 1996 |
|